Revolutionizing the Mind: Gestala Secures $21M Funding in Record Time

Revolutionizing Brain-Computer Interface Technology: A Look at Gestala’s Groundbreaking Innovations

In the realm of brain-computer interface (BCI) technology, significant advancements are being made by companies like Elon Musk’s Neuralink and OpenAI-backed Merge Labs in the United States. However, on the other side of the globe, Chinese entrepreneur Phoenix Peng is making waves with his two startups: NeuroXess, specializing in implantable BCI systems, and Gestala, focusing on non-invasive ultrasound-based BCIs.

Gestala, just two months after its inception, secured an impressive $21.6 million in funding at a valuation ranging from $100 million to $200 million. This funding round, co-led by Guosheng Capital and Dalton Venture with participation from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin, and Seas Capital, was oversubscribed, with commitments exceeding $58 million.

Founder and CEO Phoenix Peng shared that this funding round marks the largest early-stage investment in China’s BCI industry. The capital raised will be allocated towards research and development efforts, team expansion from 15 to around 35 employees by the end of the year, and the establishment of a manufacturing facility in China. Gestala aims to finalize its first-generation prototype by the year-end.

Amid a surge in investment in ultrasound technology within the global BCI industry, Gestala stands out as the first ultrasound BCI company in China. Peng envisions ultrasound as the next frontier in BCI technology, offering broader access to the brain and novel ways to interact with neural activity.

One of the key advantages of ultrasound technology, according to Peng, is its non-invasiveness, which mitigates the risks associated with traditional brain surgery. This technology has the capability to monitor a larger portion of the brain, including deep neural circuits, and can precisely stimulate or suppress neural activity without the need for surgical intervention.

Despite escalating geopolitical tensions, Phoenix Peng remains optimistic about the potential for collaboration between the U.S. and China in deep-technology research. Peng highlights the complementary strengths of both countries, with China offering extensive clinical research capabilities and efficient supply chains, while the U.S. boasts world-class scientific expertise.

Gestala is actively exploring various applications for its ultrasound BCI technology. The startup’s primary focus is on chronic pain management, a prevalent issue in both the U.S. and China. Studies suggest that ultrasound stimulation can effectively reduce pain levels, making it a promising avenue for intervention.

Additionally, Gestala is investigating the use of its technology in addressing mental health conditions such as depression, PTSD, autism, and OCD, as well as in stroke rehabilitation. The company’s long-term goals include applications in Alzheimer’s disease, essential tremor, and Parkinson’s disease.

One of Gestala’s key competitive advantages lies in its agility and scalability. By leveraging China’s robust manufacturing ecosystem, the company believes it can expedite the transition from development to production compared to international competitors.

Furthermore, Gestala is collaborating with major Chinese hospitals to accelerate clinical trials at a fraction of the cost of similar studies in the U.S. or Europe. Simultaneously, the company is establishing an “Ultrasound Brain Bank,” a comprehensive clinical dataset aimed at training AI models to interpret brain signals and support future neurological diagnostics.